Basic analysis of anti-allergic agent MMKY-01, which accelerating drug sensitivity to gemicitabine in pancreatic cancer cell.

点击翻译按钮获取中文摘要

The present study demonstrated that MMKY-01 accelerates drug sensitivity to gemcitabine via decreasing RRM1 expression in pancreatic and gall bladder (GB) cancer cells. The reduced RRM1 expression was derived through ubiquitin-proteosome pathway in pancreatic cancer. Further analysis revealed that MMKY-01 rendered gemcitabine resistant GB cancer cell to apoptosis. These results indicated that MMKY-01 plus gemcitabine is possibly effective to pancreatic as well as GB cancer. Especially, MMKY-01 treatment was revealed to reverse the gemcitabine resistance in GB cancer.